| Autor: |
Guilherme Harada, Maria Fernanda Batistuzzo Vicentini Neffa, Renata Colombo Bonadio, Elizabeth Zambrano Mendoza, Rafael Caparica, Letícia Leone Lauricella, Teresa Yae Takagaki, Felipe Santa Rosa Roitberg, Ricardo Mingarini Terra, Gilberto De Castro Jr |
| Jazyk: |
English<br />Portuguese |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
Jornal Brasileiro de Pneumologia, Vol 47, Iss 3 (2021) |
| Druh dokumentu: |
article |
| ISSN: |
1806-3756 |
| DOI: |
10.36416/1806-3756/e20200378 |
| Popis: |
ABSTRACT Objective: Adjuvant chemotherapy (AC) improves survival of patients with resected non-small cell lung cancer (NSCLC). However, the cisplatin-vinorelbine regimen has been associated with a significant risk of clinically relevant toxicity. We sought to evaluate the effectiveness, safety, and feasibility of AC for NSCLC patients in a real-world setting. Methods: This was a single-center, retrospective cohort study of patients with stage I-III NSCLC undergoing surgery with curative intent between 2009 and 2018. AC was administered at the discretion of physicians. The patients were divided into two groups: AC group and no AC (control) group. Study outcomes included overall survival (OS) and recurrence-free survival (RFS), as well as the safety profile and feasibility of the cisplatin-vinorelbine regimen in a real-world setting. Results: The study involved 231 patients, 80 of whom received AC. Of those, 55 patients received the cisplatin-vinorelbine regimen. Survival analyses stratified by tumor stage showed that patients with stage II NSCLC in the AC group had better RFS (p = 0.036) and OS (p = 0.017) than did those in the no AC group. Among patients with stage III NSCLC in the AC group, RFS was better (p < 0.001) and there was a trend toward improved OS (p = 0.060) in comparison with controls. Of those who received the cisplatin-vinorelbine regimen, 29% had grade 3-4 febrile neutropenia, and 9% died of toxicity. Conclusions: These results support the benefit of AC for NSCLC patients in a real-world setting. However, because the cisplatin-vinorelbine regimen was associated with alarming rates of toxicity, more effective and less toxic alternatives should be investigated. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
